Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

ly there is no marketed treatment for DGF; when DGF is diagnosed the patient is supported with dialysis and other supportive care.

The investigational drug candidate QPI-1002 is a siRNA designed to temporarily inhibit the expression of the pro-apoptotic gene, p53. This siRNA is based on Quark's proprietary, patented therapeutic concept of temporarily inhibiting the expression of p53 to protect normal cells from acute injury. QPI-1002 is a chemically modified siRNA discovered by Quark with structure covered under licenses from Silence Therapeutics and from Alnylam Pharmaceuticals. QPI-1002 was the first systemically administered siRNA in a human clinical study.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. QPI-1007, which is a siRNA that utilizes a novel siRNA structure developed by Quark and is being evaluated in advanced IND-e
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Kewaunee Scientific Corporation (Nasdaq: KEQU ... quarterly cash dividend by 9% to twelve cents per ... with the dividend payable on September 22, 2014 to ... September 8, 2014. About Kewaunee Scientific ... Corporation is a recognized global leader in the design, ...
(Date:8/27/2014)... N.J. and NINGBO, China ... and the Ningbo Menovo Pharmaceutical Co., Ltd, ("Menovo") today ... the development of generic pharmaceuticals, primarily targeting ... of the agreement, Amerigen and Menovo will jointly develop ... United States . Menovo will be responsible for ...
(Date:8/27/2014)... 27, 2014 Ambit Biosciences (Nasdaq: AMBI ), ... targeting unmet needs in oncology, autoimmune and inflammatory disease, today ... Conference to be held at The New York Palace Hotel ... 3-4, 2014. Alan Fuhrman , Ambit,s CFO, ... drug candidate, quizartinib, at 1:10 p.m. ET on Wednesday, September ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2Ambit Announces Participation At Baird 2014 Health Care Conference 2
... Inc. (NYSE Amex: INO ), which is advancing ... that Dr. J. Joseph Kim, President and CEO, will present ... Healthcare Conference taking place December 13-14 at the Waldorf-Astoria in ... 13 10:50 am ET A live and archived ...
... Dec. 11, 2011   TetraLogic Pharmaceuticals , a biopharmaceutical ... treat cancer, today announced the oral presentation of new ... the 53rd ASH Annual Meeting and Exposition in San ... M. D. Anderson Cancer Center, demonstrated that TL32711 induces ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 2Inovio Pharmaceuticals to Present at Oppenheimer Investor Conference 3TetraLogic Pharmaceuticals Announces Oral Presentation on Smac Mimetic TL32711 at American Society of Hematology (ASH) Annual Meeting 2
(Date:8/27/2014)... DiaSorin has announced that their new webinar , ... guest speaker Dr. Gregory A. Plotnikoff, a physician and ... Integrative Medicine. Dr. Plotnikoff serves as an integrative medicine ... Healing and as Senior Consultant, Center for Health Care ... as a co-editor of the new journal Global Advances ...
(Date:8/27/2014)... August 28, 2014 National Resident ... in the Association for Medical Education in Europe (AMEE) ... Milan, Italy August 30 – September 3, 2014. ... the international medical education community, share the benefits of ... strengthen resident physician placement in countries throughout the world. ...
(Date:8/27/2014)... Delta, a reliable supplier of high quality ... D7R Dozers to its used bulldozer collection. ... that all these items are offered with deep discounts. ... Delta’s market share in the coming September. , ... offer; he has much confidence in the discounted Used ...
(Date:8/27/2014)... Philadelphia, PA. Inc. magazine ranked Holganix as ... an exclusive ranking of the nation’s fastest-growing privately held ... the most important segment of the economy - America’s ... as members of the Inc. 500 list include Dell, ... of world’s greatest companies have had their start on ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Reviewing the ... will now be easier for the public when using ... that are promoted in all 50 states in the ... , The different insurers that are generating the rates ... possible for adults to use the programmed system without ...
Breaking Medicine News(10 mins):Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3Health News:National Resident Matching Program International (NRMPI) to Exhibit at the 2014 AMEE Conference 2Health News:Reliable Supplier Delta Adds New Items To Its Used Bulldozer Collection 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:Home Insurance Prices for All 50 States Now Supplied at Consumer Insurance Portal Online 2
... WASHINGTON, May 12 Speaker Nancy Pelosi released ... the Social Security and Medicare Trustees, which was released ... of the Social Security and Medicare trust funds. ... left behind a record of recession, deficits and debt, ...
... In a meeting today with President Obama and ... Inc. (REI) drew praise for their innovative employee health ... Association (RILA).Following the meeting, President Obama referred to the ... and Safeway President and CEO Steven Burd, as "some ...
... to hear world voices, especially voices from Africa, about ... , - Dr. Paul Zeitz, GAA executive directorWASHINGTON, May ... than 12,000 health advocates and organizations around the world, ... Zeitz called for a worldwide response to fix ...
... PARS) today reported results for the first quarter ended March ... million, or $0.14 per share, for the first quarter 2009 ... per share, in the first quarter 2008. Cash and short-term ... in net loss for the first quarter 2009 vs. first ...
... Nektar Therapeutics (Nasdaq: NKTR ) is scheduled ... Care Conference in Boston at the Boston InterContinental Hotel on ... will be accessible via a Webcast through a link posted ... website: http://www.nektar.com . This ...
... BurrellesLuce is sponsoring a multifaceted look at "Advanced PR Strategies," one of ... Summit, to take place Sunday, May 17, through Tuesday, May 19, in ... ... BurrellesLuce is sponsoring a multifaceted look at "Advanced PR Strategies," ...
Cached Medicine News:Health News:President Obama Praises Retailers as Part of the Health Care Solution 2Health News:GAA Calls For a Worldwide Response to President Obama's Global Health Budget Shortfalls 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 4Health News:Pharmos Corporation Reports 2009 First Quarter Results 5Health News:BurrellesLuce Sponsoring Track on 'Advanced PR Strategies' At Annual Industry Summit to Be Held May 17-19 in New York 2Health News:BurrellesLuce Sponsoring Track on 'Advanced PR Strategies' At Annual Industry Summit to Be Held May 17-19 in New York 3
... from Poly (L-Lactic Acid) material which has ... fixation throughout the healing process. The ... it is absorbed into the tissue or ... press-fit anchor design allows for accurate placement ...
... better. How can one of the leading ... becoming more convenient to use in all ... TwinFix Suture Anchor with Needles combines the ... and timesaving anchor inserter and needle delivery ...
... Anchor is the smallest, strongest anchor ... in placement into even the smallest ... 3-0 or 4-0 ETHIBOND EXCEL suture ... cutting swaged needles. The kit includes ...
... Threaded Anchors (3.0mm) are ideal for soft tissue ... surgical applications. The FASTIN threaded anchor technology offers ... surgical sites. If you need a threaded anchor ... the FASTIN anchor is the anchor for you. ...
Medicine Products: